# Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors

> **NCT00105170** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 13 (actual)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** hCBE-11

## Key facts

- **NCT ID:** NCT00105170
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2013-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105170, "Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00105170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*